Bone Biologics Corporation – NASDAQ:BBLG

Add to watchlist

$2.251

+1.30

+136.94%

Market open

Closed in 29 minutes

-21.49%

month

-21.49%

quarter

-79.57%

year

Market Cap	2.26M
Enterprise value	N/A

P/E	-1.92
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	0.48
PEG ratio	-0.02
EPS	-22.63

Revenue	N/A
EBITDA	-8.06M
Income	-6.10M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Bone Biologics Corporation (NASDAQ:BBLG): Profit margin
Jun 2023	0	-1.76M
Sep 2023	0	-1.91M
Dec 2023	0	-1.54M
Mar 2024	0	-865.97K

Bone Biologics Financials Estimate

Q Y

Bone Biologics Corporation (NASDAQ:BBLG): Analyst Estimates
Mar 2024	0	-865.97K
Sep 2025	0	-4.46M
Oct 2025	0	-786.50K
Dec 2025	0	-793.11K

Analysts Price target
Financials & Ratios estimates

Bone Biologics Corporation (NASDAQ:BBLG): Earnings per share (EPS)
2023-03-30	-0.22	-0.18
2023-05-15	-45.05	-6.91
2023-08-14	-1.5	-1.69

Bone Biologics Corporation (NASDAQ:BBLG): Debt to assets
Jun 2023	7623047	1.93M	25.32%
Sep 2023	4976344	1.18M	23.78%
Dec 2023	3737763	831.40K	22.24%
Mar 2024	3839574	164.62K	4.29%

Bone Biologics Corporation (NASDAQ:BBLG): Cash Flow
Jun 2023	-3.63M	4.45M
Sep 2023	-2.55M	0
Dec 2023	-2.01M	591.99K
Mar 2024	-1.30M	1.50M

Bone Biologics alternative data

Bone Biologics Corporation (NASDAQ:BBLG): Employee count
Aug 2023	2
Sep 2023	2
Oct 2023	2
Nov 2023	2
Dec 2023	2
Jan 2024	2
Feb 2024	2
Mar 2024	2
Apr 2024	2
May 2024	2
Jun 2024	2
Jul 2024	2

Bone Biologics
Hedge Funds Holdings Q1 2023

1.18% -50.02%

of BBLG is owned by hedge funds

3 -9

hedge funds hold BBLG stock

52.01K -2.21M

shares is hold by hedge funds

BBLG hedge funds holdings changes

Bone Biologics
Insider Trading

Bone Biologics Corporation (NASDAQ:BBLG): Insider trades (number of shares)
Period	Buy	Sel
Aug 2023	7600	0
Sep 2023	7000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	6 Sep 2023	WALSH DEINA H officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	6,700	$0.71	$4,757
Purchase	6 Sep 2023	WALSH DEINA H officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	300	$0.7	$210
Purchase	31 Aug 2023	FRELICK JEFF officer: Chief Executive Officer officer: Chief Executive Officer	Common Stock	7,600	$0.66	$5,024
Purchase	2 Jan 2020	HANKEY DON director, 10 percent owner, officer: Chairman o.. director, 10 percent owner, off..	Common Stock	195,000	$1	$195,000
Purchase	2 Jan 2020	HANKEY BRET director director	Common Stock	195,000	$1	$195,000
Purchase	6 Aug 2019	HANKEY DON director, 10 percent owner, officer: Chairman o.. director, 10 percent owner, off..	Common Stock	553,191	N/A	N/A
Purchase	6 Aug 2019	HANKEY BRET director director	Common Stock	553,191	N/A	N/A
Purchase	15 Jul 2019	HANKEY BRET director director	Common Stock	85,106	N/A	N/A
Purchase	15 Jul 2019	HANKEY DON director, 10 percent owner, officer: Chairman o.. director, 10 percent owner, off..	Common Stock	85,106	N/A	N/A
Purchase	20 Jun 2019	HANKEY BRET director director	Common Stock	1,063,830	N/A	N/A

BBLG insider trading transactions

Bone Biologics
Executives

Insider	Age	Since	Compensation
Mr. Jeffrey Frelick (1966) Pres & Chief Executive Officer	59		$240,000

Bone Biologics
Latest News

Friday, 2 August 2024
08:00	Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds	businesswire.com
Thursday, 20 June 2024
08:00	First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion	businesswire.com
Wednesday, 6 March 2024
16:15	Bone Biologics Announces Closing of $2.0 Million Public Offering	businesswire.com
Monday, 4 March 2024
09:15	Bone Biologics Announces Pricing of $2.0 Million Public Offering	businesswire.com
Friday, 1 March 2024
08:00	Bone Biologics Reports Progress With NB1 Clinical Program	businesswire.com
Friday, 17 November 2023
08:37	Why Is Bone Biologics (BBLG) Stock Down 38% Today?	InvestorPlace
Thursday, 16 November 2023
07:46	Why Is Bone Biologics (BBLG) Stock Up 84% Today?	InvestorPlace
Tuesday, 11 July 2023
15:06	Penny Stocks to Watch: Why Is ELOX Stock Skyrocketing?	PennyStocks
Wednesday, 21 June 2023
07:49	Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)	Benzinga
Thursday, 15 June 2023
09:22	Bone Biologics stock plummets more than 50% after stock offering prices at deep discount	Market Watch
08:40	Why Is Bone Biologics (BBLG) Stock Down 52% Today?	InvestorPlace
Wednesday, 14 December 2022
11:51	Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch	PennyStocks
Monday, 12 December 2022
14:51	7 Hot Penny Stocks Under $1 To Watch This Week	PennyStocks
Thursday, 17 March 2022
13:54	Best Penny Stocks To Buy? 4 Biotech Stocks To Watch Right Now	PennyStocks
Monday, 10 January 2022
15:50	BBLG Stock Alert: 7 Things to Know as Bone Biologics Skyrockets Today	InvestorPlace
15:13	3 Penny Stocks to Watch With the Stock Market Down Today	PennyStocks
10:38	Why Are Bone Biologics Shares Surging On Monday?	Benzinga
Monday, 18 October 2021
08:30	Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq	Business Wire
Friday, 15 October 2021
12:00	WallachBeth Capital Announces Completion of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering	PRNewsWire

Frequently Asked Questions (FAQ)

What's the price of Bone Biologics stock today?

One share of Bone Biologics stock can currently be purchased for approximately $2.25.
When is Bone Biologics's next earnings date?

Unfortunately, Bone Biologics's (BBLG) next earnings date is currently unknown.
Does Bone Biologics pay dividends?

No, Bone Biologics does not pay dividends.
How much money does Bone Biologics make?

Bone Biologics has a market capitalization of 2.26M. Bone Biologics made a loss 8.95M US dollars in net income (profit) last year or -$1.69 on an earnings per share basis.
What is Bone Biologics's stock symbol?

Bone Biologics Corporation is traded on the NASDAQ under the ticker symbol "BBLG".
What is Bone Biologics's primary industry?

Company operates in the Healthcare sector and Medical - Devices industry.
How do i buy shares of Bone Biologics?

Shares of Bone Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Bone Biologics's key executives?
Bone Biologics's management team includes the following people:
- Mr. Jeffrey Frelick Pres & Chief Executive Officer(age: 59, pay: $240,000)
How many employees does Bone Biologics have?

As Jul 2024, Bone Biologics employs 2 workers.
When Bone Biologics went public?

Bone Biologics Corporation is publicly traded company for more then 3 years since IPO on 13 Oct 2021.
What is Bone Biologics's official website?

The official website for Bone Biologics is bonebiologics.com.
Where are Bone Biologics's headquarters?

Bone Biologics is headquartered at 2 Burlington Woods Drive, Burlington, MA.
How can i contact Bone Biologics?

Bone Biologics's mailing address is 2 Burlington Woods Drive, Burlington, MA and company can be reached via phone at +7 815524452.

Bone Biologics Corporation

bonebiologics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Medical - Devices

Sector:

Healthcare

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

+7 815524452

2 Burlington Woods Drive
Burlington, MA 01803

CIK: 0001419554
ISIN: US0980705018
CUSIP: 098070303